n |
35 |
15 |
|
Age |
57.2 ± 12.5 |
46.7 ± 15.5 |
0.15 |
Gender (Female) |
16 (45.7%) |
7 (46.7%) |
0.95 |
BMI (Kg/m2) |
30.7 ± 4.6 |
32.5 ± 6.2 |
0.15 |
Atopy - yes (%) |
12 (40.0%) |
13 (92.9%) |
<0.01 |
Chronic Rhinosinusitis - yes (%) |
20 (66.7%) |
8 (57.1%) |
0.54 |
Nasal polyps - yes (%) |
14 (46.7%) |
7 (50.0%) |
0.84 |
Bronchiectasis - yes (%) |
2 (6.7%) |
0 (0.0%) |
0.32 |
ACQ post treatment |
1.4 ± 1.1 |
1.7 ± 0.9 |
0.36 |
ACQ decrease post treatment |
-0.7 ± 1.2 |
- 0.6 ± 1.1 |
0.68 |
Blood eosinophils pre treatment |
0.4 [0.2 - 0.7] |
0.3
[0.1 - 0.8] |
0.70 |
Blood eosinophils post treatment |
0.0 [0.0 - 0.02] |
0.0
[0.0 - 0.15] |
0.10 |
Sputum eosinophils pre treatment |
7.5 [1.5 - 31.1] |
18.3
[6.7 - 58.8] |
0.17 |
Sputum eosinophils post treatment |
0.0 [0.0 - 0.5] |
0.0
[0.0 - 9.2] |
0.08 |
ICS dose post treatment (mcg/day) |
1250 [1000 - 2000] |
1000 [625 - 1750] |
0.32 |
OCS dose post treatment (mg/day) |
5.0 [0.0 - 10.0] |
6.3
[0.0 - 10.6] |
0.79 |
FEV1 increase post treatment |
0.16 ± 0.41 |
0.13 ± 0.54 |
0.30 |